| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiration, Artificial | 51 | 2022 | 2628 | 2.870 |
Why?
|
| Acute Lung Injury | 25 | 2022 | 367 | 2.650 |
Why?
|
| Pulmonary Alveoli | 7 | 2022 | 652 | 1.590 |
Why?
|
| Positive-Pressure Respiration | 24 | 2020 | 639 | 1.390 |
Why?
|
| Sepsis | 23 | 2023 | 2585 | 1.140 |
Why?
|
| Tidal Volume | 20 | 2019 | 488 | 1.110 |
Why?
|
| Fluid Therapy | 13 | 2023 | 579 | 1.080 |
Why?
|
| Intensive Care Units | 37 | 2022 | 3745 | 0.920 |
Why?
|
| Shock, Septic | 14 | 2021 | 768 | 0.890 |
Why?
|
| Lung Injury | 6 | 2016 | 422 | 0.850 |
Why?
|
| Neuromuscular Blocking Agents | 4 | 2019 | 129 | 0.820 |
Why?
|
| Respiratory Insufficiency | 11 | 2021 | 1230 | 0.800 |
Why?
|
| Critical Care | 19 | 2017 | 2696 | 0.780 |
Why?
|
| Blood Gas Analysis | 8 | 2018 | 379 | 0.760 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 2 | 2011 | 111 | 0.730 |
Why?
|
| Ventilator-Induced Lung Injury | 5 | 2017 | 120 | 0.720 |
Why?
|
| Albuterol | 2 | 2011 | 213 | 0.720 |
Why?
|
| Carbon Monoxide | 4 | 2018 | 547 | 0.630 |
Why?
|
| Ventilators, Mechanical | 2 | 2020 | 288 | 0.630 |
Why?
|
| Prone Position | 5 | 2022 | 196 | 0.620 |
Why?
|
| Steroids | 2 | 2016 | 929 | 0.550 |
Why?
|
| Respiratory Mechanics | 2 | 2020 | 699 | 0.540 |
Why?
|
| Glucocorticoids | 4 | 2020 | 2161 | 0.540 |
Why?
|
| Positive-Pressure Respiration, Intrinsic | 1 | 2015 | 10 | 0.520 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2006 | 161 | 0.520 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 559 | 0.480 |
Why?
|
| Hospital Mortality | 29 | 2022 | 5294 | 0.470 |
Why?
|
| Preventive Medicine | 1 | 2016 | 246 | 0.460 |
Why?
|
| APACHE | 18 | 2022 | 267 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2019 | 10209 | 0.430 |
Why?
|
| Dexamethasone | 1 | 2020 | 1948 | 0.420 |
Why?
|
| Humans | 226 | 2023 | 761504 | 0.420 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 3084 | 0.410 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 3204 | 0.410 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 179 | 0.400 |
Why?
|
| Neuromuscular Blockade | 5 | 2022 | 146 | 0.400 |
Why?
|
| Ventilator Weaning | 4 | 2021 | 164 | 0.400 |
Why?
|
| Pandemics | 8 | 2022 | 8654 | 0.390 |
Why?
|
| Primary Prevention | 2 | 2017 | 1186 | 0.390 |
Why?
|
| Critical Illness | 15 | 2020 | 2723 | 0.370 |
Why?
|
| Nitric Oxide | 5 | 2006 | 2135 | 0.360 |
Why?
|
| Control Groups | 2 | 2007 | 104 | 0.340 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2011 | 322 | 0.340 |
Why?
|
| Polymorphism, Genetic | 11 | 2015 | 4243 | 0.330 |
Why?
|
| Shock | 6 | 2017 | 314 | 0.320 |
Why?
|
| Clinical Trials as Topic | 14 | 2022 | 8002 | 0.320 |
Why?
|
| Muscle, Smooth, Vascular | 15 | 2000 | 1493 | 0.310 |
Why?
|
| Atracurium | 2 | 2019 | 51 | 0.310 |
Why?
|
| Catheterization, Swan-Ganz | 6 | 2011 | 86 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2018 | 3245 | 0.300 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2014 | 819 | 0.290 |
Why?
|
| Male | 139 | 2023 | 360804 | 0.290 |
Why?
|
| Middle Aged | 112 | 2022 | 220895 | 0.290 |
Why?
|
| Severity of Illness Index | 21 | 2022 | 15842 | 0.280 |
Why?
|
| Protein C | 6 | 2010 | 133 | 0.280 |
Why?
|
| Splenic Rupture | 1 | 2006 | 26 | 0.270 |
Why?
|
| Administration, Inhalation | 5 | 2020 | 1157 | 0.270 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 426 | 0.270 |
Why?
|
| Pulmonary Gas Exchange | 5 | 2020 | 379 | 0.260 |
Why?
|
| Vasoconstrictor Agents | 7 | 2023 | 654 | 0.260 |
Why?
|
| Sulfonamides | 2 | 2014 | 1978 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2010 | 1880 | 0.260 |
Why?
|
| Work of Breathing | 1 | 2006 | 56 | 0.260 |
Why?
|
| Female | 127 | 2023 | 392644 | 0.260 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2018 | 499 | 0.250 |
Why?
|
| Lung | 16 | 2022 | 10000 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 12 | 2000 | 1578 | 0.250 |
Why?
|
| Biomedical Research | 5 | 2017 | 3429 | 0.240 |
Why?
|
| Aged | 79 | 2022 | 169289 | 0.230 |
Why?
|
| Adult | 87 | 2022 | 221177 | 0.230 |
Why?
|
| Aerospace Medicine | 1 | 2005 | 95 | 0.230 |
Why?
|
| Aircraft | 1 | 2005 | 130 | 0.230 |
Why?
|
| Treatment Failure | 7 | 2021 | 2645 | 0.230 |
Why?
|
| Terminal Care | 3 | 2006 | 1760 | 0.230 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 151 | 0.220 |
Why?
|
| Double-Blind Method | 14 | 2022 | 12341 | 0.220 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2022 | 975 | 0.220 |
Why?
|
| Prognosis | 26 | 2022 | 29625 | 0.220 |
Why?
|
| Pulmonary Artery | 18 | 2006 | 1927 | 0.220 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 231 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 3 | 2022 | 1943 | 0.220 |
Why?
|
| Personnel Selection | 1 | 2005 | 196 | 0.210 |
Why?
|
| Blood Glucose | 6 | 2017 | 6391 | 0.210 |
Why?
|
| High-Frequency Ventilation | 2 | 2017 | 88 | 0.210 |
Why?
|
| Psychological Tests | 1 | 2005 | 640 | 0.210 |
Why?
|
| Oxygen | 11 | 2022 | 4227 | 0.210 |
Why?
|
| Heparin | 9 | 2000 | 1634 | 0.200 |
Why?
|
| Treatment Outcome | 39 | 2023 | 64680 | 0.200 |
Why?
|
| Alanine | 2 | 2021 | 609 | 0.200 |
Why?
|
| Pulmonary Edema | 3 | 2013 | 409 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2015 | 416 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2014 | 3028 | 0.200 |
Why?
|
| Qa-SNARE Proteins | 1 | 2021 | 52 | 0.200 |
Why?
|
| Air Pollutants | 2 | 2006 | 2896 | 0.190 |
Why?
|
| Creatine Kinase | 3 | 2016 | 685 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 8 | 2013 | 1702 | 0.190 |
Why?
|
| Survival Analysis | 18 | 2018 | 10090 | 0.190 |
Why?
|
| Ergocalciferols | 2 | 2012 | 110 | 0.190 |
Why?
|
| Hyperglycemia | 2 | 2013 | 1376 | 0.190 |
Why?
|
| Survival Rate | 11 | 2020 | 12725 | 0.190 |
Why?
|
| Risk Factors | 37 | 2022 | 74206 | 0.190 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 710 | 0.180 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 125 | 0.180 |
Why?
|
| Respiratory Function Tests | 7 | 2016 | 1682 | 0.180 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2016 | 137 | 0.180 |
Why?
|
| Hemodynamics | 10 | 2013 | 4159 | 0.180 |
Why?
|
| Interleukin-6 | 7 | 2022 | 3208 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 2 | 2012 | 1380 | 0.170 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 172 | 0.170 |
Why?
|
| Pituitary-Adrenal System | 1 | 2003 | 552 | 0.170 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 807 | 0.170 |
Why?
|
| Endothelium | 1 | 2022 | 765 | 0.160 |
Why?
|
| Thorax | 1 | 2022 | 555 | 0.160 |
Why?
|
| Antiviral Agents | 3 | 2021 | 3060 | 0.160 |
Why?
|
| Immune System Diseases | 1 | 2021 | 256 | 0.160 |
Why?
|
| United States | 24 | 2020 | 72334 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2022 | 1175 | 0.160 |
Why?
|
| Hypotension | 2 | 2023 | 879 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2003 | 701 | 0.160 |
Why?
|
| Water-Electrolyte Balance | 6 | 2016 | 325 | 0.160 |
Why?
|
| Research Design | 7 | 2020 | 6180 | 0.160 |
Why?
|
| Interleukin-8 | 4 | 2011 | 695 | 0.150 |
Why?
|
| Central Venous Pressure | 2 | 2016 | 79 | 0.150 |
Why?
|
| Troponin T | 2 | 2014 | 780 | 0.150 |
Why?
|
| Biopsy | 4 | 2016 | 6766 | 0.150 |
Why?
|
| Medicare | 1 | 2016 | 6770 | 0.150 |
Why?
|
| Vitamins | 2 | 2019 | 1635 | 0.150 |
Why?
|
| Survivors | 4 | 2021 | 2371 | 0.150 |
Why?
|
| Acute Kidney Injury | 4 | 2012 | 1924 | 0.150 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 411 | 0.150 |
Why?
|
| Respiratory Dead Space | 2 | 2015 | 31 | 0.150 |
Why?
|
| Prospective Studies | 33 | 2023 | 54425 | 0.140 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2017 | 12 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8529 | 0.140 |
Why?
|
| Insulin | 2 | 2008 | 6596 | 0.140 |
Why?
|
| Haplotypes | 5 | 2012 | 2713 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2012 | 851 | 0.140 |
Why?
|
| Vitamin D Deficiency | 2 | 2019 | 1388 | 0.140 |
Why?
|
| Oximetry | 2 | 2017 | 459 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2012 | 1723 | 0.130 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2020 | 1462 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2015 | 1934 | 0.130 |
Why?
|
| Vasopressins | 1 | 2017 | 351 | 0.130 |
Why?
|
| Military Personnel | 1 | 2005 | 1246 | 0.130 |
Why?
|
| Inflammation | 4 | 2014 | 10773 | 0.130 |
Why?
|
| Pulmonary Circulation | 8 | 1994 | 737 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2020 | 15936 | 0.130 |
Why?
|
| Time Factors | 18 | 2023 | 39967 | 0.130 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 781 | 0.120 |
Why?
|
| Hypoglycemia | 2 | 2015 | 883 | 0.120 |
Why?
|
| Expert Testimony | 1 | 2017 | 364 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2019 | 553 | 0.120 |
Why?
|
| Forms and Records Control | 2 | 2013 | 158 | 0.120 |
Why?
|
| Airway Resistance | 4 | 2008 | 406 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2020 | 970 | 0.120 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2015 | 130 | 0.120 |
Why?
|
| Mortality | 4 | 2020 | 2901 | 0.110 |
Why?
|
| Angiotensin II | 1 | 2017 | 849 | 0.110 |
Why?
|
| Lung Diseases, Obstructive | 2 | 1992 | 308 | 0.110 |
Why?
|
| Third-Party Consent | 1 | 2013 | 66 | 0.110 |
Why?
|
| Informed Consent | 2 | 2013 | 1008 | 0.110 |
Why?
|
| Odds Ratio | 5 | 2021 | 9646 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2014 | 17904 | 0.110 |
Why?
|
| Risk Assessment | 13 | 2020 | 23995 | 0.110 |
Why?
|
| Lung Diseases | 6 | 2020 | 1909 | 0.110 |
Why?
|
| Renal Insufficiency | 2 | 2020 | 809 | 0.110 |
Why?
|
| Terminology as Topic | 2 | 2012 | 1530 | 0.100 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2008 | 277 | 0.100 |
Why?
|
| Genes, bcl-2 | 1 | 2012 | 119 | 0.100 |
Why?
|
| Logistic Models | 13 | 2017 | 13255 | 0.100 |
Why?
|
| gamma-Linolenic Acid | 1 | 2011 | 16 | 0.100 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 12059 | 0.100 |
Why?
|
| Amiloride | 5 | 1998 | 116 | 0.100 |
Why?
|
| Liver Failure | 1 | 2014 | 250 | 0.100 |
Why?
|
| Cardiac Volume | 1 | 2012 | 197 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 1134 | 0.100 |
Why?
|
| Respiratory Rate | 3 | 2021 | 176 | 0.100 |
Why?
|
| Infusions, Intravenous | 5 | 2008 | 2219 | 0.100 |
Why?
|
| Permeability | 1 | 2013 | 723 | 0.090 |
Why?
|
| Partial Pressure | 3 | 2018 | 245 | 0.090 |
Why?
|
| Propanolamines | 1 | 1991 | 163 | 0.090 |
Why?
|
| Guinea Pigs | 8 | 1994 | 1310 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 103 | 0.090 |
Why?
|
| Blood Pressure | 10 | 2017 | 8481 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2017 | 1475 | 0.090 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2006 | 146 | 0.090 |
Why?
|
| Cohort Studies | 15 | 2023 | 41487 | 0.090 |
Why?
|
| Patient Selection | 3 | 2021 | 4244 | 0.090 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2010 | 48 | 0.090 |
Why?
|
| Conscious Sedation | 3 | 2019 | 532 | 0.090 |
Why?
|
| Interleukin-10 | 2 | 2006 | 1175 | 0.090 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 6310 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2011 | 3810 | 0.080 |
Why?
|
| Disease Notification | 1 | 2010 | 95 | 0.080 |
Why?
|
| Vasoconstriction | 4 | 1994 | 592 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 1265 | 0.080 |
Why?
|
| Renal Replacement Therapy | 3 | 2020 | 282 | 0.080 |
Why?
|
| Environmental Monitoring | 2 | 2006 | 1460 | 0.080 |
Why?
|
| Epidemiologic Methods | 2 | 2004 | 1336 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 4 | 2017 | 2691 | 0.080 |
Why?
|
| Myocardium | 3 | 2012 | 4726 | 0.080 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 1875 | 0.080 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2009 | 29 | 0.080 |
Why?
|
| Elafin | 1 | 2009 | 31 | 0.080 |
Why?
|
| von Willebrand Factor | 3 | 2012 | 673 | 0.080 |
Why?
|
| Forecasting | 2 | 2016 | 2928 | 0.080 |
Why?
|
| Enteral Nutrition | 2 | 2012 | 794 | 0.080 |
Why?
|
| Radiography | 4 | 2017 | 6965 | 0.080 |
Why?
|
| Sensitivity and Specificity | 6 | 2011 | 14666 | 0.080 |
Why?
|
| Hospitalization | 4 | 2022 | 10723 | 0.080 |
Why?
|
| Sarcoidosis | 2 | 2005 | 521 | 0.080 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2008 | 43 | 0.080 |
Why?
|
| Dopamine | 2 | 2005 | 1607 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 10766 | 0.080 |
Why?
|
| Hemodiafiltration | 1 | 2008 | 18 | 0.080 |
Why?
|
| Predictive Value of Tests | 11 | 2016 | 15266 | 0.080 |
Why?
|
| Vasodilator Agents | 3 | 2020 | 973 | 0.080 |
Why?
|
| Aged, 80 and over | 22 | 2020 | 58976 | 0.080 |
Why?
|
| Adiponectin | 1 | 2014 | 1113 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 6814 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2017 | 2571 | 0.070 |
Why?
|
| Belgium | 2 | 2004 | 118 | 0.070 |
Why?
|
| Respiration | 2 | 1991 | 1657 | 0.070 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2011 | 561 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2009 | 452 | 0.070 |
Why?
|
| Length of Stay | 4 | 2019 | 6425 | 0.070 |
Why?
|
| Antioxidants | 2 | 2015 | 1668 | 0.070 |
Why?
|
| Proportional Hazards Models | 8 | 2018 | 12463 | 0.070 |
Why?
|
| Retrospective Studies | 15 | 2022 | 80636 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2022 | 6484 | 0.070 |
Why?
|
| Anti-Infective Agents | 3 | 2010 | 983 | 0.070 |
Why?
|
| Carboxyhemoglobin | 2 | 2018 | 83 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 2009 | 365 | 0.070 |
Why?
|
| Acute Disease | 7 | 2019 | 7237 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2012 | 1154 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 2422 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 784 | 0.070 |
Why?
|
| Heme Oxygenase-1 | 1 | 2009 | 366 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 2 | 2017 | 565 | 0.070 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2008 | 197 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2015 | 1509 | 0.070 |
Why?
|
| Desmosine | 1 | 2006 | 19 | 0.070 |
Why?
|
| Clinical Protocols | 3 | 2012 | 1440 | 0.070 |
Why?
|
| Heart Atria | 1 | 2012 | 1345 | 0.070 |
Why?
|
| Phenotype | 5 | 2018 | 16591 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 1600 | 0.070 |
Why?
|
| Hemoperitoneum | 1 | 2006 | 38 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 211 | 0.070 |
Why?
|
| Platelet Count | 2 | 2020 | 781 | 0.070 |
Why?
|
| Gene Frequency | 6 | 2014 | 3606 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 445 | 0.070 |
Why?
|
| Peptide Fragments | 3 | 2008 | 5112 | 0.070 |
Why?
|
| Fibrinolysis | 1 | 2007 | 332 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2021 | 1186 | 0.070 |
Why?
|
| Splenic Artery | 1 | 2006 | 57 | 0.060 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 254 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1991 | 1241 | 0.060 |
Why?
|
| Mannose-Binding Lectin | 1 | 2007 | 145 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 101 | 0.060 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 527 | 0.060 |
Why?
|
| Patient Positioning | 2 | 2020 | 326 | 0.060 |
Why?
|
| Lymphotoxin-alpha | 1 | 2005 | 93 | 0.060 |
Why?
|
| Personality Tests | 1 | 2005 | 81 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 678 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 1886 | 0.060 |
Why?
|
| Barotrauma | 2 | 2002 | 39 | 0.060 |
Why?
|
| Cardiac Output | 4 | 2009 | 831 | 0.060 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 795 | 0.060 |
Why?
|
| Case-Control Studies | 12 | 2011 | 22176 | 0.060 |
Why?
|
| Decision Making | 2 | 2012 | 3929 | 0.060 |
Why?
|
| Polysomnography | 2 | 2022 | 1848 | 0.060 |
Why?
|
| Vascular Resistance | 6 | 1998 | 930 | 0.060 |
Why?
|
| Florida | 1 | 2006 | 431 | 0.060 |
Why?
|
| Incidence | 4 | 2019 | 21353 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 908 | 0.060 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 3 | 2011 | 48 | 0.060 |
Why?
|
| Natriuretic Peptides | 1 | 2006 | 155 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2007 | 755 | 0.060 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2012 | 992 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2006 | 385 | 0.060 |
Why?
|
| Euthanasia, Passive | 1 | 2004 | 64 | 0.060 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 20098 | 0.060 |
Why?
|
| Energy Intake | 1 | 2012 | 2134 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 350 | 0.060 |
Why?
|
| Sex Factors | 4 | 2015 | 10552 | 0.060 |
Why?
|
| Troponin | 1 | 2007 | 502 | 0.060 |
Why?
|
| Disease Management | 1 | 2015 | 2508 | 0.060 |
Why?
|
| Intelligence Tests | 1 | 2005 | 503 | 0.060 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2009 | 515 | 0.060 |
Why?
|
| Child Development | 1 | 2015 | 2306 | 0.060 |
Why?
|
| Kidney | 3 | 2015 | 7048 | 0.060 |
Why?
|
| Leukocyte Elastase | 1 | 2004 | 114 | 0.060 |
Why?
|
| Chronic Disease | 10 | 2015 | 9318 | 0.060 |
Why?
|
| Glucose | 1 | 2015 | 4346 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2018 | 5079 | 0.050 |
Why?
|
| Cell Division | 8 | 2000 | 4465 | 0.050 |
Why?
|
| Expert Systems | 2 | 1994 | 79 | 0.050 |
Why?
|
| Comorbidity | 5 | 2020 | 10508 | 0.050 |
Why?
|
| Physical Examination | 1 | 2009 | 1255 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 4853 | 0.050 |
Why?
|
| Calibration | 1 | 2006 | 818 | 0.050 |
Why?
|
| Genotype | 7 | 2015 | 12990 | 0.050 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2004 | 175 | 0.050 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 39106 | 0.050 |
Why?
|
| Ancillary Services, Hospital | 1 | 2002 | 23 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2007 | 1687 | 0.050 |
Why?
|
| Mental Recall | 2 | 2021 | 1214 | 0.050 |
Why?
|
| Prevalence | 5 | 2022 | 15732 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20570 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2005 | 621 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2011 | 1797 | 0.050 |
Why?
|
| Pulmonary Medicine | 1 | 2004 | 221 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 63 | 0.050 |
Why?
|
| Health Services Research | 1 | 2010 | 1812 | 0.050 |
Why?
|
| Smoking | 2 | 2020 | 9053 | 0.050 |
Why?
|
| Propranolol | 1 | 1984 | 489 | 0.050 |
Why?
|
| Bicarbonates | 3 | 2014 | 292 | 0.050 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2002 | 45 | 0.050 |
Why?
|
| HLA-D Antigens | 1 | 2002 | 129 | 0.050 |
Why?
|
| Patient Discharge | 3 | 2023 | 3443 | 0.050 |
Why?
|
| Analysis of Variance | 5 | 2007 | 6228 | 0.050 |
Why?
|
| Dyspnea | 1 | 2009 | 1347 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2003 | 602 | 0.050 |
Why?
|
| Wounds and Injuries | 3 | 2013 | 2491 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 1984 | 328 | 0.050 |
Why?
|
| Lung Compliance | 1 | 2001 | 200 | 0.050 |
Why?
|
| ROC Curve | 4 | 2011 | 3579 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2013 | 3424 | 0.050 |
Why?
|
| Furosemide | 2 | 2016 | 170 | 0.050 |
Why?
|
| International Cooperation | 1 | 2007 | 1422 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 1386 | 0.050 |
Why?
|
| Age Factors | 6 | 2016 | 18395 | 0.050 |
Why?
|
| Glycine | 1 | 2004 | 663 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 635 | 0.050 |
Why?
|
| Blood Transfusion | 2 | 2008 | 1298 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2012 | 2091 | 0.050 |
Why?
|
| Coronary Care Units | 1 | 2002 | 235 | 0.050 |
Why?
|
| Utilization Review | 1 | 2002 | 382 | 0.050 |
Why?
|
| Time | 2 | 2018 | 546 | 0.050 |
Why?
|
| Health Status | 2 | 2014 | 4077 | 0.050 |
Why?
|
| Angiography | 1 | 2006 | 1595 | 0.050 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 3826 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2001 | 2496 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2013 | 3537 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2006 | 937 | 0.040 |
Why?
|
| Carbon Dioxide | 3 | 2001 | 1147 | 0.040 |
Why?
|
| Medical Futility | 1 | 2021 | 136 | 0.040 |
Why?
|
| Guideline Adherence | 2 | 2008 | 2220 | 0.040 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2003 | 451 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2016 | 3816 | 0.040 |
Why?
|
| Academic Medical Centers | 3 | 2018 | 2759 | 0.040 |
Why?
|
| Computers | 1 | 2022 | 593 | 0.040 |
Why?
|
| Cattle | 5 | 1999 | 3849 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2008 | 1179 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2006 | 1139 | 0.040 |
Why?
|
| Spleen | 1 | 2006 | 2295 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2021 | 26198 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 7879 | 0.040 |
Why?
|
| Infusions, Parenteral | 2 | 1994 | 397 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2358 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 208 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 413 | 0.040 |
Why?
|
| Linear Models | 4 | 2015 | 5871 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 1505 | 0.040 |
Why?
|
| Cause of Death | 4 | 2017 | 3683 | 0.040 |
Why?
|
| Pirenzepine | 1 | 1999 | 116 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2010 | 6534 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 7045 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2012 | 3879 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 3415 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2002 | 415 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2020 | 271 | 0.040 |
Why?
|
| Diuretics | 2 | 2016 | 610 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2010 | 1521 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 1668 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 2005 | 4486 | 0.040 |
Why?
|
| Edema | 1 | 2022 | 766 | 0.040 |
Why?
|
| Pulmonary Embolism | 4 | 1992 | 2567 | 0.040 |
Why?
|
| Resuscitation | 2 | 2017 | 673 | 0.040 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 3688 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 842 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 2243 | 0.040 |
Why?
|
| Verapamil | 1 | 1999 | 242 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2007 | 2490 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1984 | 732 | 0.040 |
Why?
|
| Communication | 1 | 2012 | 3873 | 0.040 |
Why?
|
| Ventilation | 1 | 1999 | 128 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2011 | 3242 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 5789 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2012 | 3979 | 0.040 |
Why?
|
| Pneumonia | 4 | 2013 | 2143 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 988 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2003 | 628 | 0.040 |
Why?
|
| Chest Wall Oscillation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Infection Control | 1 | 2004 | 981 | 0.040 |
Why?
|
| Ischemia | 1 | 2006 | 1882 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 737 | 0.040 |
Why?
|
| Europe | 1 | 2004 | 3422 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2019 | 5247 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 2850 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 3 | 2008 | 7390 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2872 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 1999 | 607 | 0.030 |
Why?
|
| Aftercare | 1 | 2023 | 914 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2002 | 787 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2020 | 1572 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 26125 | 0.030 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 1302 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4811 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1418 | 0.030 |
Why?
|
| Glucosamine | 1 | 1996 | 128 | 0.030 |
Why?
|
| Catecholamines | 1 | 2017 | 386 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 4 | 2017 | 7407 | 0.030 |
Why?
|
| Transaminases | 1 | 2016 | 198 | 0.030 |
Why?
|
| Inhalation | 1 | 2016 | 143 | 0.030 |
Why?
|
| Molecular Epidemiology | 2 | 2009 | 469 | 0.030 |
Why?
|
| Amino Acids | 1 | 2002 | 1718 | 0.030 |
Why?
|
| Calcitonin | 1 | 2017 | 329 | 0.030 |
Why?
|
| Leukocytes | 1 | 2003 | 2026 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 694 | 0.030 |
Why?
|
| Epitopes | 1 | 2002 | 2503 | 0.030 |
Why?
|
| Nutritional Support | 1 | 2017 | 173 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2012 | 2927 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 1999 | 962 | 0.030 |
Why?
|
| Quality of Life | 2 | 2023 | 13367 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2003 | 1819 | 0.030 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 1007 | 0.030 |
Why?
|
| Random Allocation | 2 | 2016 | 2395 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2005 | 1813 | 0.030 |
Why?
|
| Phospholipases A | 1 | 1995 | 204 | 0.030 |
Why?
|
| Carbohydrate Sequence | 3 | 2000 | 411 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3305 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2014 | 87 | 0.030 |
Why?
|
| Alleles | 4 | 2009 | 6863 | 0.030 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2006 | 189 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2011 | 1126 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2021 | 6567 | 0.030 |
Why?
|
| Spirometry | 2 | 2015 | 929 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6075 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 1996 | 406 | 0.030 |
Why?
|
| Delphi Technique | 2 | 2008 | 846 | 0.030 |
Why?
|
| Receptors, Adiponectin | 1 | 2014 | 81 | 0.030 |
Why?
|
| Registries | 1 | 2010 | 8224 | 0.030 |
Why?
|
| Multiple Organ Failure | 2 | 2008 | 387 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 3734 | 0.030 |
Why?
|
| Creatinine | 2 | 2011 | 1899 | 0.030 |
Why?
|
| Anticoagulants | 2 | 2008 | 4812 | 0.030 |
Why?
|
| Papio | 1 | 2015 | 669 | 0.030 |
Why?
|
| Antimalarials | 1 | 2020 | 907 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 728 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 865 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 492 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2021 | 2846 | 0.030 |
Why?
|
| Animals | 20 | 2015 | 168459 | 0.030 |
Why?
|
| Berlin | 1 | 2012 | 23 | 0.030 |
Why?
|
| Hypertension | 3 | 2020 | 8540 | 0.030 |
Why?
|
| Goals | 1 | 2018 | 711 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 1329 | 0.030 |
Why?
|
| Respiratory Aspiration | 1 | 2013 | 89 | 0.030 |
Why?
|
| Respiratory Muscles | 1 | 1993 | 142 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2017 | 624 | 0.030 |
Why?
|
| Pressure Ulcer | 1 | 1994 | 157 | 0.030 |
Why?
|
| Mental Competency | 1 | 2013 | 176 | 0.030 |
Why?
|
| Hypertrophy | 1 | 1994 | 561 | 0.030 |
Why?
|
| Cytokines | 1 | 2007 | 7396 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1994 | 1334 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2004 | 4330 | 0.020 |
Why?
|
| Computer Graphics | 1 | 1994 | 340 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1996 | 926 | 0.020 |
Why?
|
| Amidohydrolases | 1 | 2012 | 159 | 0.020 |
Why?
|
| Knowledge Bases | 1 | 2012 | 97 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2011 | 186 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 3808 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2018 | 1315 | 0.020 |
Why?
|
| Proxy | 1 | 2012 | 151 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 3598 | 0.020 |
Why?
|
| Classification | 1 | 2011 | 127 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2017 | 908 | 0.020 |
Why?
|
| Hydrogen | 1 | 1991 | 172 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 125 | 0.020 |
Why?
|
| Ventricular Function | 1 | 1993 | 406 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1994 | 1152 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 5840 | 0.020 |
Why?
|
| Polycythemia | 1 | 1991 | 124 | 0.020 |
Why?
|
| Serpins | 1 | 2012 | 247 | 0.020 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 1989 | 41 | 0.020 |
Why?
|
| Decision Support Techniques | 2 | 2012 | 1998 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2011 | 256 | 0.020 |
Why?
|
| Etretinate | 1 | 1989 | 6 | 0.020 |
Why?
|
| Molecular Weight | 2 | 2006 | 2186 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2016 | 6343 | 0.020 |
Why?
|
| Risk | 2 | 2015 | 9610 | 0.020 |
Why?
|
| Immune Complex Diseases | 1 | 1989 | 50 | 0.020 |
Why?
|
| DNA | 1 | 2003 | 7212 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 12148 | 0.020 |
Why?
|
| Epithelium | 1 | 1994 | 1603 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2009 | 96 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 1989 | 153 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2012 | 423 | 0.020 |
Why?
|
| Canada | 2 | 2004 | 2122 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4920 | 0.020 |
Why?
|
| HIV Infections | 1 | 2015 | 17351 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1988 | 66 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 299 | 0.020 |
Why?
|
| Ultrasonography | 3 | 2012 | 5972 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2018 | 1310 | 0.020 |
Why?
|
| Hydrostatic Pressure | 1 | 2008 | 98 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2016 | 1403 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 310 | 0.020 |
Why?
|
| Isotretinoin | 1 | 1989 | 134 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2002 | 5914 | 0.020 |
Why?
|
| Boston | 3 | 2007 | 9326 | 0.020 |
Why?
|
| Choline | 1 | 1989 | 515 | 0.020 |
Why?
|
| Organ Size | 1 | 1993 | 2254 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 180 | 0.020 |
Why?
|
| Liver Failure, Acute | 1 | 2009 | 181 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3510 | 0.020 |
Why?
|
| Documentation | 1 | 2013 | 897 | 0.020 |
Why?
|
| Proteomics | 1 | 2020 | 3849 | 0.020 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2007 | 83 | 0.020 |
Why?
|
| Pulmonary Heart Disease | 1 | 1986 | 34 | 0.020 |
Why?
|
| Visitors to Patients | 1 | 2006 | 36 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 217 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2013 | 8631 | 0.020 |
Why?
|
| Sodium | 1 | 1991 | 1588 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 656 | 0.020 |
Why?
|
| Tissue Survival | 1 | 2006 | 119 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2010 | 787 | 0.020 |
Why?
|
| Education, Continuing | 1 | 2006 | 114 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 3067 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 1258 | 0.020 |
Why?
|
| Vitamin D | 1 | 2019 | 3303 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 833 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 1371 | 0.020 |
Why?
|
| Adolescent | 9 | 2008 | 88319 | 0.020 |
Why?
|
| Peptides | 1 | 1997 | 4358 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 18252 | 0.020 |
Why?
|
| Vasculitis | 1 | 1989 | 521 | 0.020 |
Why?
|
| Rats, Inbred WKY | 2 | 1995 | 151 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 585 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1803 | 0.020 |
Why?
|
| Rats, Inbred SHR | 2 | 1995 | 186 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 1648 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5336 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2008 | 539 | 0.010 |
Why?
|
| Microcirculation | 1 | 2009 | 1273 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 1989 | 702 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2009 | 1494 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2012 | 4021 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 857 | 0.010 |
Why?
|
| Human Experimentation | 1 | 2005 | 123 | 0.010 |
Why?
|
| Propensity Score | 1 | 2012 | 1913 | 0.010 |
Why?
|
| Massachusetts | 2 | 2010 | 8830 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2005 | 293 | 0.010 |
Why?
|
| Placebos | 1 | 2008 | 1667 | 0.010 |
Why?
|
| Homozygote | 1 | 2009 | 1776 | 0.010 |
Why?
|
| Cells, Cultured | 5 | 1999 | 18965 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 1379 | 0.010 |
Why?
|
| Hematocrit | 2 | 1998 | 623 | 0.010 |
Why?
|
| New Zealand | 1 | 2004 | 358 | 0.010 |
Why?
|
| Probability | 1 | 2009 | 2477 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 1996 | 618 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 2176 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2006 | 348 | 0.010 |
Why?
|
| Necrosis | 1 | 2007 | 1611 | 0.010 |
Why?
|
| Analgesia | 1 | 2008 | 461 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2735 | 0.010 |
Why?
|
| Muscle Weakness | 1 | 2006 | 412 | 0.010 |
Why?
|
| Spain | 1 | 2004 | 487 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2005 | 563 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 1994 | 273 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2011 | 1126 | 0.010 |
Why?
|
| Pyridines | 1 | 2014 | 2875 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 11460 | 0.010 |
Why?
|
| Heterozygote | 1 | 2009 | 2787 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 2000 | 17635 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 1192 | 0.010 |
Why?
|
| Drug Industry | 1 | 2008 | 788 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2012 | 3023 | 0.010 |
Why?
|
| Computer Systems | 2 | 1994 | 470 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2003 | 712 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14605 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2008 | 962 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 4028 | 0.010 |
Why?
|
| Attitude of Health Personnel | 2 | 2006 | 3889 | 0.010 |
Why?
|
| Geography | 1 | 2003 | 656 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12690 | 0.010 |
Why?
|
| Total Quality Management | 1 | 2002 | 265 | 0.010 |
Why?
|
| Blood Vessels | 3 | 1992 | 1113 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 594 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 3085 | 0.010 |
Why?
|
| Problem Solving | 2 | 1994 | 441 | 0.010 |
Why?
|
| Australia | 1 | 2004 | 1250 | 0.010 |
Why?
|
| Confidentiality | 1 | 2005 | 609 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2012 | 2720 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2004 | 469 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 1986 | 743 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 7827 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 1998 | 0.010 |
Why?
|
| Warfarin | 1 | 1989 | 1483 | 0.010 |
Why?
|
| Rats | 4 | 1998 | 23742 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1664 | 0.010 |
Why?
|
| Echocardiography | 1 | 2012 | 4989 | 0.010 |
Why?
|
| Heart Rate | 1 | 1991 | 4195 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2010 | 2979 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 1787 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12974 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 1213 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 2819 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1999 | 240 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2011 | 3415 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1991 | 4936 | 0.010 |
Why?
|
| Electrophoresis, Cellulose Acetate | 1 | 1997 | 16 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1997 | 81 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 5492 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 1303 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2015 | 12953 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 4016 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2011 | 6240 | 0.010 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 1998 | 108 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2002 | 1156 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1998 | 8181 | 0.010 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 1996 | 15 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 1866 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 13639 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1996 | 206 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2006 | 2244 | 0.010 |
Why?
|
| Alkalies | 1 | 1996 | 44 | 0.010 |
Why?
|
| Research | 1 | 2004 | 1982 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2007 | 2986 | 0.010 |
Why?
|
| Chromatography, Agarose | 1 | 1995 | 29 | 0.010 |
Why?
|
| Patient Participation | 1 | 2005 | 1444 | 0.010 |
Why?
|
| Disaccharides | 1 | 1996 | 170 | 0.010 |
Why?
|
| Skin | 1 | 2009 | 4484 | 0.010 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1997 | 344 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 4544 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 1964 | 0.010 |
Why?
|
| Family | 1 | 2006 | 3194 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 3113 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 14031 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 1995 | 197 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 3322 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 2118 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2007 | 3575 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1994 | 272 | 0.010 |
Why?
|
| Software | 1 | 2008 | 4434 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2012 | 4575 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 4618 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2002 | 2495 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 1993 | 51 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 59243 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1999 | 1132 | 0.010 |
Why?
|
| Estradiol Congeners | 1 | 1992 | 23 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1996 | 701 | 0.010 |
Why?
|
| Heart Failure | 2 | 1994 | 11669 | 0.010 |
Why?
|
| Child | 2 | 2013 | 80153 | 0.010 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1992 | 117 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 42230 | 0.010 |
Why?
|
| Microcomputers | 1 | 1993 | 141 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 12441 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1991 | 33 | 0.010 |
Why?
|
| Depression | 1 | 2012 | 8124 | 0.010 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1991 | 59 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1991 | 235 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1991 | 124 | 0.010 |
Why?
|
| Aerosols | 1 | 1993 | 635 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 1496 | 0.010 |
Why?
|
| Surface Tension | 1 | 1989 | 43 | 0.010 |
Why?
|
| Asthma | 1 | 1989 | 6234 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 1999 | 1402 | 0.010 |
Why?
|
| Recurrence | 2 | 1992 | 8465 | 0.010 |
Why?
|
| Methacholine Compounds | 1 | 1989 | 35 | 0.010 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1989 | 42 | 0.010 |
Why?
|
| Pulmonary Surfactants | 1 | 1989 | 162 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 1989 | 216 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1989 | 220 | 0.000 |
Why?
|
| Prothrombin Time | 1 | 1989 | 117 | 0.000 |
Why?
|
| Temperature | 1 | 1995 | 2226 | 0.000 |
Why?
|
| Catheterization | 1 | 1994 | 1428 | 0.000 |
Why?
|
| Partial Thromboplastin Time | 1 | 1989 | 204 | 0.000 |
Why?
|
| Aorta | 1 | 1995 | 2042 | 0.000 |
Why?
|
| User-Computer Interface | 1 | 1994 | 1400 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1989 | 1031 | 0.000 |
Why?
|
| Liposomes | 1 | 1989 | 784 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 1972 | 0.000 |
Why?
|
| Kinetics | 1 | 1991 | 6374 | 0.000 |
Why?
|
| Blood Coagulation | 1 | 1989 | 1154 | 0.000 |
Why?
|
| Heart Transplantation | 1 | 1994 | 3233 | 0.000 |
Why?
|
| Heart Diseases | 1 | 1991 | 2781 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1991 | 6377 | 0.000 |
Why?
|
| Mice | 1 | 1996 | 81525 | 0.000 |
Why?
|
| Neoplasms | 1 | 1992 | 22170 | 0.000 |
Why?
|